JP2010530364A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010530364A5 JP2010530364A5 JP2010510888A JP2010510888A JP2010530364A5 JP 2010530364 A5 JP2010530364 A5 JP 2010530364A5 JP 2010510888 A JP2010510888 A JP 2010510888A JP 2010510888 A JP2010510888 A JP 2010510888A JP 2010530364 A5 JP2010530364 A5 JP 2010530364A5
- Authority
- JP
- Japan
- Prior art keywords
- variable domain
- antagonist
- vegf
- cancer
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000005557 antagonist Substances 0.000 claims 38
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 16
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 16
- 108060003951 Immunoglobulin Proteins 0.000 claims 12
- 102000018358 immunoglobulin Human genes 0.000 claims 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 238000009472 formulation Methods 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 150000007523 nucleic acids Chemical group 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 206010035664 Pneumonia Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 3
- 206010064930 age-related macular degeneration Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000004927 fusion Effects 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 230000002685 pulmonary effect Effects 0.000 claims 3
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 claims 2
- 102000004142 Trypsin Human genes 0.000 claims 2
- 108090000631 Trypsin Proteins 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 206010006451 bronchitis Diseases 0.000 claims 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 2
- 102000058223 human VEGFA Human genes 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 239000012588 trypsin Substances 0.000 claims 2
- 201000001178 Bacterial Pneumonia Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 102000016387 Pancreatic elastase Human genes 0.000 claims 1
- 108010067372 Pancreatic elastase Proteins 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 108010019160 Pancreatin Proteins 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000009977 dual effect Effects 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 239000000710 homodimer Substances 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229940055695 pancreatin Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93363207P | 2007-06-06 | 2007-06-06 | |
| GBGB0724331.4A GB0724331D0 (en) | 2007-12-13 | 2007-12-13 | Compositions for pulmonary delivery |
| PCT/GB2008/050407 WO2008149150A2 (en) | 2007-06-06 | 2008-06-04 | Polypeptides, antibody variable domains and antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010530364A JP2010530364A (ja) | 2010-09-09 |
| JP2010530364A5 true JP2010530364A5 (cg-RX-API-DMAC7.html) | 2011-07-21 |
Family
ID=39791116
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010510887A Active JP5444215B2 (ja) | 2007-06-06 | 2008-06-04 | ポリペプチド、抗体可変ドメインおよびアンタゴニスト |
| JP2010510888A Pending JP2010530364A (ja) | 2007-06-06 | 2008-06-04 | ポリペプチド、抗体可変ドメインおよびアンタゴニスト |
| JP2010510886A Expired - Fee Related JP5325211B2 (ja) | 2007-06-06 | 2008-06-04 | ポリペプチド、抗体可変ドメインおよびアンタゴニスト |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010510887A Active JP5444215B2 (ja) | 2007-06-06 | 2008-06-04 | ポリペプチド、抗体可変ドメインおよびアンタゴニスト |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010510886A Expired - Fee Related JP5325211B2 (ja) | 2007-06-06 | 2008-06-04 | ポリペプチド、抗体可変ドメインおよびアンタゴニスト |
Country Status (31)
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
| DK1888641T3 (da) | 2005-05-18 | 2012-04-23 | Ablynx Nv | Serumalbuminbindende proteiner |
| DE102005023617A1 (de) | 2005-05-21 | 2006-11-23 | Aspre Ag | Verfahren zum Mischen von Farben in einem Display |
| GB0724331D0 (en) | 2007-12-13 | 2008-01-23 | Domantis Ltd | Compositions for pulmonary delivery |
| JP2010528647A (ja) * | 2007-06-06 | 2010-08-26 | ドマンティス リミテッド | ポリペプチド、抗体可変ドメインおよびアンタゴニスト |
| CA2688434A1 (en) | 2007-06-06 | 2008-12-11 | Domantis Limited | Polypeptides, antibody variable domains and antagonists |
| TW200938222A (en) * | 2007-12-13 | 2009-09-16 | Glaxo Group Ltd | Compositions for pulmonary delivery |
| JP2011516603A (ja) | 2008-04-17 | 2011-05-26 | アブリンクス エン．ヴェー． | 血清タンパク質と結合することが可能なペプチド、並びにこれを含む化合物、構築物及びポリペプチド |
| SI3722310T1 (sl) | 2008-06-25 | 2025-01-31 | Novartis Ag | Stabilna in topna protitelesa, ki zavirajo vegf |
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| CA2744055A1 (en) * | 2008-11-26 | 2010-06-03 | Glaxo Group Limited | Polypeptides, antibody variable domains & antagonists |
| WO2010081787A1 (en) | 2009-01-14 | 2010-07-22 | Domantis Limited | IMPROVED TNFα ANTAGONISM, PROPHYLAXIS & THERAPY WITH REDUCED ORGAN NECROSIS |
| ES2654929T3 (es) * | 2009-02-19 | 2018-02-15 | Glaxo Group Limited | Variantes de unión de anti-albúmina de suero mejoradas |
| CA2750477A1 (en) | 2009-02-19 | 2010-08-26 | Stephen Duffield | Improved anti-tnfr1 polypeptides, antibody variable domains & antagonists |
| EA028178B1 (ru) * | 2009-02-19 | 2017-10-31 | Глэксо Груп Лимитед | Улучшенные связывающие сывороточный альбумин варианты |
| EP2401298A1 (en) | 2009-02-24 | 2012-01-04 | Glaxo Group Limited | Antigen-binding constructs |
| US20120107330A1 (en) * | 2009-07-16 | 2012-05-03 | Adriaan Allart Stoop | Antagonists, uses & methods for partially inhibiting tnfr1 |
| BR112012001681A2 (pt) | 2009-07-16 | 2019-09-24 | Graxo Group Ltd | domínios variáveis de ligação de anti-albumina sérica aperfeiçoados |
| US20110223149A1 (en) * | 2009-10-14 | 2011-09-15 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| AU2010311640B2 (en) | 2009-10-27 | 2015-01-29 | Glaxo Group Limited | Stable anti-TNFR1 polypeptides, antibody variable domains & antagonists |
| WO2011095545A1 (en) | 2010-02-05 | 2011-08-11 | Ablynx Nv | Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same |
| WO2011144751A1 (en) | 2010-05-20 | 2011-11-24 | Glaxo Group Limited | Improved anti-serum albumin binding variants |
| WO2012020143A1 (en) | 2010-08-13 | 2012-02-16 | Glaxo Group Limited | Improved anti-serum albumin binding variants |
| EP2606065A2 (en) * | 2010-08-20 | 2013-06-26 | GlaxoSmithKline Intellectual Property Development Limited | Improved anti-serum albumin binding variants |
| ES2618586T3 (es) | 2010-09-16 | 2017-06-21 | Baliopharm Ag | Anticuerpo anti-huTNFR1 |
| US20130266567A1 (en) | 2010-12-01 | 2013-10-10 | Haren Arulanantham | Anti-serum albumin binding single variable domains |
| WO2012104227A1 (en) | 2011-02-02 | 2012-08-09 | Glaxo Group Limited | Novel antigen binding proteins |
| US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| EP3569243A1 (en) * | 2011-06-28 | 2019-11-20 | Inhibrx, LP | Serpin fusion polypeptides and methods of use thereof |
| US10400029B2 (en) | 2011-06-28 | 2019-09-03 | Inhibrx, Lp | Serpin fusion polypeptides and methods of use thereof |
| KR101632620B1 (ko) * | 2011-07-27 | 2016-06-23 | 글락소 그룹 리미티드 | Ｆｃ 도메인에 융합된 항ｖｅｇｆ 단일 가변 도메인 |
| KR102162413B1 (ko) * | 2011-08-17 | 2020-10-07 | 글락소 그룹 리미티드 | 변형된 단백질 및 펩티드 |
| GB2497138A (en) * | 2011-12-02 | 2013-06-05 | Randox Lab Ltd | Biomarkers for stroke and stroke subtype diagnosis. |
| RS57704B1 (sr) | 2012-07-13 | 2018-12-31 | Roche Glycart Ag | Bispecifična anti-vegf/anti-ang-2 antitela i njihova primena u lečenju vaskularnih bolesti oka |
| WO2014111550A1 (en) | 2013-01-17 | 2014-07-24 | Glaxosmithkline Intellectual Property Development Limited | Modified anti-serum albumin binding proteins |
| CA2897345A1 (en) | 2013-01-31 | 2014-08-07 | Glaxo Group Limited | Method of producing a protein |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| MA41374A (fr) | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
| AU2016381964B2 (en) | 2015-12-30 | 2024-02-15 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
| GB201617622D0 (en) * | 2016-10-18 | 2016-11-30 | VIB VZW and Universiteit Gent | Means and methods to treat inflammation |
| RU2625010C1 (ru) * | 2016-11-10 | 2017-07-11 | Илья Петрович Приколаб | Экспрессионный плазмидный вектор для экспрессии активной формы TNFR1-Fc и способ получения рекомбинантного белка |
| TW202323287A (zh) | 2016-11-28 | 2023-06-16 | 日商中外製藥股份有限公司 | 包含抗原結合域與運送部分的多胜肽 |
| KR20230073346A (ko) | 2016-11-28 | 2023-05-25 | 추가이 세이야쿠 가부시키가이샤 | 리간드 결합 활성을 조정 가능한 리간드 결합 분자 |
| UY37651A (es) * | 2017-03-31 | 2018-10-31 | Swedish Orphan Biovitrum Ab Publ | Polipéptido de unión al il-1r-i |
| AU2018359532C9 (en) * | 2017-11-01 | 2025-02-13 | Allogene Therapeutics, Inc. | Modified caspase-9 polypeptides and methods of use thereof |
| TW202348632A (zh) | 2017-11-28 | 2023-12-16 | 日商中外製藥股份有限公司 | 含有抗原結合域及運輸部分之多胜肽 |
| BR112020010248A2 (pt) | 2017-11-28 | 2020-11-10 | Chugai Seiyaku Kabushiki Kaisha | molécula de ligação do ligante tendo atividade de ligação do ligante ajustável |
| WO2019169341A1 (en) | 2018-03-02 | 2019-09-06 | Kodiak Sciences Inc. | Il-6 antibodies and fusion constructs and conjugates thereof |
| EP3807312A4 (en) | 2018-05-30 | 2022-07-20 | Chugai Seiyaku Kabushiki Kaisha | POLYPEPTIDE COMPRISING AN AGGREECAN-BINDING DOMAIN AND A TRANSPORT FRACTION |
| JP7428661B2 (ja) * | 2018-05-30 | 2024-02-06 | 中外製薬株式会社 | Ｉｌ－１ｒ１結合ドメインおよび運搬部分を含むポリペプチド |
| EP3623798B1 (de) * | 2018-09-13 | 2021-11-03 | Euroimmun Medizinische Labordiagnostika AG | Verfahren und vorrichtung zum erfassen und darstellen eines immunfluoreszenzbildes einer biologischen probe |
| JP2022512798A (ja) * | 2018-10-25 | 2022-02-07 | エフ．ホフマン－ラ ロシュ アーゲー | 抗体ＦｃＲｎ結合の改変 |
| EP3890764A2 (en) | 2018-12-06 | 2021-10-13 | CytomX Therapeutics, Inc. | Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof |
| CN111454366B (zh) * | 2019-01-21 | 2023-06-16 | 中国科学院深圳先进技术研究院 | 一种融合蛋白及其应用 |
| JP7315967B2 (ja) * | 2019-01-31 | 2023-07-27 | 積水メディカル株式会社 | 生物学的試料中の遊離ａｉｍの免疫学的分析方法及び測定キット |
| CN114786731A (zh) | 2019-10-10 | 2022-07-22 | 科达制药股份有限公司 | 治疗眼部病症的方法 |
| JP7473398B2 (ja) * | 2020-05-28 | 2024-04-23 | シスメックス株式会社 | キャリブレータ、複合体、及びＩｇＡ凝集体を測定する方法 |
| CN116847887A (zh) | 2020-08-27 | 2023-10-03 | 伊诺西治疗公司 | 治疗自身免疫性疾病和癌症的方法和组合物 |
| WO2022117569A1 (en) | 2020-12-02 | 2022-06-09 | Oncurious Nv | A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer |
| CN115181751A (zh) * | 2021-04-02 | 2022-10-14 | 苏州博腾生物制药有限公司 | 靶向白蛋白的嵌合抗原受体及其使用方法 |
| CN114657162B (zh) * | 2022-03-04 | 2023-06-16 | 华南理工大学 | 一种具有血管内皮细胞保护功能的抗氧化五肽及其应用 |
| CN115112704B (zh) * | 2022-06-21 | 2025-07-15 | 中特检验集团有限公司 | 一种光热发电有机热载体热稳定性检测方法 |
| AR129879A1 (es) | 2022-07-08 | 2024-10-09 | Novo Nordisk As | Compuestos de isvd altamente potentes capaces de sustituir al fviii(a) |
| WO2025049818A1 (en) | 2023-08-29 | 2025-03-06 | Enosi Therapeutics Corporation | Tnfr1 antagonists lacking agonist activity and uses thereof |
| CN119909772B (zh) * | 2025-04-01 | 2025-06-20 | 安徽一帆新材料科技有限公司 | 用于净水的再生阴树脂及其制备方法 |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2148299B (en) | 1983-09-01 | 1988-01-06 | Hybritech Inc | Antibody compositions of therapeutic agents having an extended serum half-life |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| GB8725529D0 (en) | 1987-10-30 | 1987-12-02 | Delta Biotechnology Ltd | Polypeptides |
| JP3095168B2 (ja) | 1988-02-05 | 2000-10-03 | エル． モリソン，シェリー | ドメイン‐変性不変部を有する抗体 |
| DE68927933T2 (de) | 1988-09-02 | 1997-08-14 | Dyax Corp | Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen |
| ATE102631T1 (de) | 1988-11-11 | 1994-03-15 | Medical Res Council | Klonierung von immunglobulin sequenzen aus den variabelen domaenen. |
| ATE92107T1 (de) | 1989-04-29 | 1993-08-15 | Delta Biotechnology Ltd | N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen. |
| CA2016842A1 (en) | 1989-05-16 | 1990-11-16 | Richard A. Lerner | Method for tapping the immunological repertoire |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5977307A (en) | 1989-09-07 | 1999-11-02 | Alkermes, Inc. | Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| EP0585287B1 (en) | 1990-07-10 | 1999-10-13 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| EP1046421B8 (en) | 1990-12-06 | 2006-01-11 | Affymetrix, Inc. (a Delaware Corporation) | Methods and reagents for very large scale immobilized polymer synthesis |
| WO1993011236A1 (en) | 1991-12-02 | 1993-06-10 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| CA2163345A1 (en) | 1993-06-16 | 1994-12-22 | Susan Adrienne Morgan | Antibodies |
| US5702892A (en) | 1995-05-09 | 1997-12-30 | The United States Of America As Represented By The Department Of Health And Human Services | Phage-display of immunoglobulin heavy chain libraries |
| EP0859841B1 (en) | 1995-08-18 | 2002-06-19 | MorphoSys AG | Protein/(poly)peptide libraries |
| WO1997029131A1 (en) * | 1996-02-09 | 1997-08-14 | Basf Aktiengesellschaft | HUMAN ANTIBODIES THAT BIND HUMAN TNF$g(a) |
| EP1019496B1 (en) | 1997-07-07 | 2004-09-29 | Medical Research Council | In vitro sorting method |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| GB2361237A (en) | 1998-05-13 | 2001-10-17 | Diversys Ltd | Selection system |
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| WO2002043660A2 (en) | 2000-11-28 | 2002-06-06 | Mediummune, Inc | Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment |
| GB2375112A (en) | 2000-02-03 | 2002-11-06 | Domantis Ltd | Combinatorial protein domains |
| EP1263788A2 (en) | 2000-02-11 | 2002-12-11 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Identification of a domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function |
| US7115415B2 (en) * | 2000-09-15 | 2006-10-03 | Genentech, Inc. | PRO9821 nucleic acids |
| DK1399484T3 (da) | 2001-06-28 | 2010-11-08 | Domantis Ltd | Dobbelt-specifik ligand og anvendelse af denne |
| US20060073141A1 (en) * | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| GB0118689D0 (en) * | 2001-08-01 | 2001-09-19 | Psimedica Ltd | Pharmaceutical formulation |
| US20080108560A1 (en) | 2002-03-05 | 2008-05-08 | Eli Lilly And Company | Heterologous G-Csf Fusion Proteins |
| US7696320B2 (en) * | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
| EP2135879A3 (en) * | 2002-06-28 | 2010-06-23 | Domantis Limited | Ligand |
| US20060002935A1 (en) * | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
| ES2614274T3 (es) | 2002-09-06 | 2017-05-30 | Alexion Pharmaceuticals, Inc. | Procedimiento de tratamiento de asma usando anticuerpos frente al componente de complemento C5 |
| JP4317817B2 (ja) | 2002-09-06 | 2009-08-19 | アムジェン インコーポレイテッド | 治療用ヒト抗ｉｌ−１ｒ１モノクローナル抗体 |
| CA2505326A1 (en) | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Camelidae antibodies against immunoglobulin e and use thereof for the treatment of allergic disorders |
| EP1578801A2 (en) | 2002-12-27 | 2005-09-28 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
| GB0230203D0 (en) * | 2002-12-27 | 2003-02-05 | Domantis Ltd | Fc fusion |
| US20060104968A1 (en) * | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| DE602004017726D1 (de) | 2003-06-30 | 2008-12-24 | Domantis Ltd | Pegylierte Single-domain-antikörper (dAb) |
| AU2005211725B2 (en) | 2004-02-09 | 2010-07-15 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| DK1737962T3 (da) | 2004-03-24 | 2010-12-13 | Domantis Ltd | GAS1-universel leder |
| EP2324848A3 (en) * | 2004-10-21 | 2011-09-14 | Genentech, Inc. | Method for treating intraocular neovascular diseases |
| GB0521621D0 (en) * | 2005-10-24 | 2005-11-30 | Domantis Ltd | Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases |
| US20090191217A1 (en) * | 2004-12-02 | 2009-07-30 | De Wildt Ruud M | Anti-IL-1R1 Single Domain Antibodies And Therapeutic Uses |
| TW200730539A (en) * | 2005-12-01 | 2007-08-16 | Domantis Ltd | Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1 |
| AU2006321367B2 (en) | 2005-12-01 | 2011-11-03 | Domantis Limited | Competitive domain antibody formats that bind Interleukin 1 Receptor type 1 |
| HUE048024T2 (hu) | 2006-08-10 | 2020-05-28 | Roy C Levitt | Anakinra bronchiolitis obliterans szindróma kezelésében való alkalmazásra |
| JP2010507624A (ja) * | 2006-10-27 | 2010-03-11 | アブリンクス エン．ヴェー． | ポリペプチド及びタンパク質の鼻内送達 |
| CA2688434A1 (en) | 2007-06-06 | 2008-12-11 | Domantis Limited | Polypeptides, antibody variable domains and antagonists |
| JP2010528647A (ja) | 2007-06-06 | 2010-08-26 | ドマンティス リミテッド | ポリペプチド、抗体可変ドメインおよびアンタゴニスト |
-
2008
- 2008-06-03 CA CA002688434A patent/CA2688434A1/en not_active Abandoned
- 2008-06-03 AU AU2008259590A patent/AU2008259590A1/en not_active Abandoned
- 2008-06-03 CA CA002683791A patent/CA2683791A1/en not_active Abandoned
- 2008-06-03 EA EA200901494A patent/EA200901494A1/ru unknown
- 2008-06-03 CA CA002688433A patent/CA2688433A1/en not_active Abandoned
- 2008-06-03 KR KR1020107000188A patent/KR20100018040A/ko not_active Withdrawn
- 2008-06-03 MX MX2009013137A patent/MX2009013137A/es not_active Application Discontinuation
- 2008-06-04 EA EA200901495A patent/EA018723B1/ru not_active IP Right Cessation
- 2008-06-04 WO PCT/GB2008/050407 patent/WO2008149150A2/en not_active Ceased
- 2008-06-04 AR ARP080102363A patent/AR066848A1/es not_active Application Discontinuation
- 2008-06-04 PE PE2008000944A patent/PE20090323A1/es not_active Application Discontinuation
- 2008-06-04 EA EA200901491A patent/EA018129B1/ru not_active IP Right Cessation
- 2008-06-04 WO PCT/GB2008/050405 patent/WO2008149148A2/en not_active Ceased
- 2008-06-04 AR ARP080102365A patent/AR066850A1/es not_active Application Discontinuation
- 2008-06-04 PE PE2008000940A patent/PE20090322A1/es not_active Application Discontinuation
- 2008-06-04 CA CA002683823A patent/CA2683823A1/en not_active Abandoned
- 2008-06-04 BR BRPI0812268A patent/BRPI0812268A2/pt not_active IP Right Cessation
- 2008-06-04 BR BRPI0813899A patent/BRPI0813899A2/pt not_active IP Right Cessation
- 2008-06-04 SI SI200831508T patent/SI2162467T1/sl unknown
- 2008-06-04 JP JP2010510887A patent/JP5444215B2/ja active Active
- 2008-06-04 SG SG2012040275A patent/SG182151A1/en unknown
- 2008-06-04 PL PL08750800T patent/PL2162467T3/pl unknown
- 2008-06-04 EP EP13184209.8A patent/EP2746290B1/en active Active
- 2008-06-04 KR KR1020107000212A patent/KR101604274B1/ko not_active Expired - Fee Related
- 2008-06-04 EP EP08750801A patent/EP2164867A2/en not_active Withdrawn
- 2008-06-04 CA CA002688456A patent/CA2688456A1/en not_active Abandoned
- 2008-06-04 HR HRP20151024TT patent/HRP20151024T1/hr unknown
- 2008-06-04 AU AU2008259515A patent/AU2008259515A1/en not_active Abandoned
- 2008-06-04 MX MX2009012967A patent/MX2009012967A/es not_active Application Discontinuation
- 2008-06-04 AU AU2008259516A patent/AU2008259516A1/en not_active Abandoned
- 2008-06-04 EP EP13184211.4A patent/EP2746291B1/en active Active
- 2008-06-04 CN CN200880019060A patent/CN101802004A/zh active Pending
- 2008-06-04 WO PCT/GB2008/050406 patent/WO2008149149A2/en not_active Ceased
- 2008-06-04 MX MX2009013138A patent/MX2009013138A/es active IP Right Grant
- 2008-06-04 CA CA2688447A patent/CA2688447C/en active Active
- 2008-06-04 DK DK08750800.8T patent/DK2162467T3/en active
- 2008-06-04 EP EP08750802A patent/EP2162468A2/en not_active Withdrawn
- 2008-06-04 AU AU2008259514A patent/AU2008259514B2/en not_active Ceased
- 2008-06-04 KR KR1020107000213A patent/KR20100041746A/ko not_active Withdrawn
- 2008-06-04 PE PE2008000943A patent/PE20090763A1/es not_active Application Discontinuation
- 2008-06-04 EP EP08750800.8A patent/EP2162467B1/en active Active
- 2008-06-04 CN CN2008801020043A patent/CN101883788A/zh active Pending
- 2008-06-04 CN CN200880102207.2A patent/CN101778865B/zh not_active Expired - Fee Related
- 2008-06-04 EA EA200901300A patent/EA200901300A1/ru unknown
- 2008-06-04 JP JP2010510888A patent/JP2010530364A/ja active Pending
- 2008-06-04 ES ES08750800.8T patent/ES2546943T3/es active Active
- 2008-06-04 AR ARP080102362A patent/AR066847A1/es unknown
- 2008-06-04 HU HUE08750800A patent/HUE025899T2/en unknown
- 2008-06-04 MX MX2009013211A patent/MX2009013211A/es active IP Right Grant
- 2008-06-04 JP JP2010510886A patent/JP5325211B2/ja not_active Expired - Fee Related
- 2008-06-04 US US12/663,502 patent/US8398979B2/en not_active Expired - Fee Related
- 2008-06-04 BR BRPI0812795A patent/BRPI0812795C1/pt not_active IP Right Cessation
- 2008-06-04 US US12/663,506 patent/US20100247515A1/en not_active Abandoned
- 2008-06-04 SG SG2012039541A patent/SG182141A1/en unknown
- 2008-06-04 CN CN201410440384.9A patent/CN104311663B/zh not_active Expired - Fee Related
- 2008-06-04 PT PT87508008T patent/PT2162467E/pt unknown
- 2008-06-04 KR KR1020107000223A patent/KR20100040841A/ko not_active Withdrawn
- 2008-06-04 NZ NZ581372A patent/NZ581372A/en not_active IP Right Cessation
- 2008-06-06 TW TW097121295A patent/TW200911832A/zh unknown
- 2008-06-06 TW TW097121301A patent/TW200918088A/zh unknown
- 2008-06-06 CL CL2008001673A patent/CL2008001673A1/es unknown
- 2008-06-06 CL CL2008001674A patent/CL2008001674A1/es unknown
- 2008-06-06 TW TW097121265A patent/TW200911834A/zh unknown
- 2008-06-06 TW TW097121268A patent/TW200911831A/zh unknown
- 2008-06-06 TW TW097121280A patent/TW200907128A/zh unknown
- 2008-06-06 TW TW097121296A patent/TW200902551A/zh unknown
- 2008-06-06 CL CL2008001676A patent/CL2008001676A1/es unknown
- 2008-11-26 US US12/323,632 patent/US20090148437A1/en not_active Abandoned
-
2009
- 2009-10-11 IL IL201398A patent/IL201398A0/en unknown
- 2009-11-04 US US13/130,656 patent/US20110256122A1/en not_active Abandoned
- 2009-11-04 EA EA201100546A patent/EA201100546A1/ru unknown
- 2009-11-18 IL IL202204A patent/IL202204A0/en unknown
- 2009-11-27 DO DO2009000268A patent/DOP2009000268A/es unknown
- 2009-11-30 MA MA32388A patent/MA31403B1/fr unknown
- 2009-11-30 ZA ZA2009/08470A patent/ZA200908470B/en unknown
- 2009-12-14 CO CO09142782A patent/CO6251322A2/es not_active Application Discontinuation
- 2009-12-14 CO CO09142781A patent/CO6251321A2/es not_active Application Discontinuation
-
2010
- 2010-01-04 MA MA32475A patent/MA31668B1/fr unknown
- 2010-01-06 CR CR11195A patent/CR11195A/es unknown
- 2010-01-06 CR CR11194A patent/CR11194A/es not_active Application Discontinuation
-
2011
- 2011-11-17 US US13/299,030 patent/US20120134982A1/en not_active Abandoned
-
2015
- 2015-10-06 CY CY20151100886T patent/CY1116762T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010530364A5 (cg-RX-API-DMAC7.html) | ||
| JP2010528647A5 (cg-RX-API-DMAC7.html) | ||
| JP7357038B2 (ja) | 改善されたｔｎｆ結合因子 | |
| CN103748107B (zh) | 具有免疫原性较小的t细胞和/或b细胞表位的假单胞菌外毒素a | |
| CN103917557B (zh) | 具有降低的与抗药物抗体结合的经修饰的单可变结构域抗体 | |
| CN103917560B (zh) | 双特异性抗‑cxcr7免疫球蛋白单可变结构域 | |
| IL248636B2 (en) | Enhanced immunoglobulin variable sites | |
| WO2021042694A1 (zh) | 抗vegf单域抗体及其应用 | |
| TW200911831A (en) | Polypeptides, antibody variable domains & antagonists | |
| CN104105704A (zh) | Il4/il13结合重复蛋白及用途 | |
| CN103012589B (zh) | 人源抗人血管内皮细胞生长因子抗体及其应用 | |
| CA2863468A1 (en) | Pseudomonas aeruginosa pcrv binding single variable domain antibodies | |
| CN111690066B (zh) | 抗IL-4Rα的单域抗体以及应用和药物 | |
| CN114555643A (zh) | 组合物 | |
| WO2023016505A1 (zh) | Il-11人源化抗体及其应用 | |
| WO2022089108A1 (zh) | 抗il5纳米抗体及其应用 | |
| CN111825766A (zh) | 抗il-4r单域抗体及其应用 | |
| CN102617734A (zh) | 抗FGF-2抗体Dab-2及其应用 | |
| CN108191973B (zh) | 一种靶向埃博拉病毒囊膜蛋白的高亲和力单域抗体及其制备方法与应用 | |
| CN115427441B (zh) | 针对sars-cov-2的抗体 | |
| CN116135881A (zh) | 一株羊驼源纳米抗体n36及其应用 | |
| CA3251231A1 (en) | Variants of protein Z binding to thymic stromal lymphopoietin and their medical use | |
| WO2025146081A1 (zh) | B7-h3结合蛋白 | |
| CN118047870A (zh) | 靶向bcma的抗体或其抗原结合片段及其制备方法和应用 | |
| HK40070533B (zh) | 多肽 |